Optimization of a pyrazoloquinolinone class of Chkl kinase inhibitors

Saved in:
Bibliographic Details
Published inBioorganic & medicinal chemistry letters Vol. 17; no. 21; pp. 5989 - 5994
Main Authors BRNARDIC, Edward J, GARBACCIO, Robert M, RICKERT, Keith, WALSH, Eileen S, HAMILTON, Kelly, BUSER, Carolyn A, HARDWICK, James, WEIKANG TAO, BECK, Stephen C, XIANZHI MAO, LOBELL, Robert B, SEPP-LORENZINO, Laura, FRALEY, Mark E, YOUWEI YAN, IKUTA, Mari, MUNSHI, Sanjeev K, KUO, Lawrence C, KREATSOULAS, Constantine, TASBER, Edward S, STEEN, Justin T, ARRINGTON, Kenneth L, DUDKIN, Vadim Y, HARTMAN, George D, STIRDIVANT, Steven M, DRAKAS, Bob A
Format Journal Article
LanguageEnglish
Published Oxford Elsevier 2007
Subjects
Antineoplastic agents
Biological and medical sciences
General aspects
Medical sciences
Pharmacology. Drug treatments
Antineoplastic agent
Nitrogen heterocycle
Non-specific serine/threonine protein kinase
Lung
DNA damage
Lactam
Cytotoxicity
Oncology
Signal transduction
Structure activity relation
Aromatic compound
Chemical synthesis
Tumor cell
Checkpoint escape
Enzyme
Transferases
Enzyme inhibitor
Tetracyclic compound
In vitro
Cell line
DNA
Fluorine Organic compounds
Lesion
Primary amine
Chkl kinase
Pyrazoloquinolinone
Online AccessGet full text

Cover

More Information
ISSN:0960-894X
1464-3405